---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-015520"
form_type: "8-K"
ticker: "DSGN"
cik: "0001807120"
company_name: "Design Therapeutics, Inc."
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T02:59:05.214402+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Design Therapeutics reports Q2 net loss $15M; holds $359.4M cash; initial FA data expected Q4 2022

## Summary
- Net loss of $15.0M for Q2 2022; R&D expenses $11.3M; G&A expenses $4.3M.
- Cash, equivalents and securities totaled $359.4M as of June 30, 2022, providing multi-year runway.
- Initial Phase 1 single-ascending dose data for DT-216 in Friedreich ataxia expected Q4 2022.
- Clinical development for myotonic dystrophy type-1 GeneTAC program anticipated in 2023.
- Preclinical FECD program advancing; molecules showed nearly complete reduction in toxic RNA foci in vitro.

## SEC filing metadata
- accession: 0000950170-22-015520
- form_type: 8-K
- ticker: DSGN
- cik: 0001807120
- company_name: Design Therapeutics, Inc.
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1807120/000095017022015520/0000950170-22-015520-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1807120/000095017022015520/dsgn-20220808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-015520
- JSON: https://secwatch.observer/filing/0000950170-22-015520.json
- Plain text: https://secwatch.observer/filing/0000950170-22-015520.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.